Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rectal Cancer - Overview
Rectal Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rectal Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rectal Cancer - Companies Involved in Therapeutics Development
Rectal Cancer - Drug Profiles
Rectal Cancer - Dormant Projects
Rectal Cancer - Discontinued Products
Rectal Cancer - Product Development Milestones
Featured News & Press Releases
Nov 12, 2021: Apexigen announces new phase 2 clinical data on CD40 antibody sotigalimab at the SITC 2021 Annual Meeting
Feb 04, 2021: tiol Comprehensive Cancer Network provides updates on use of LONSURF (trifluridine and tipiracil) in NCCN Drugs and Biologics Compendium for colon cancer and rectal cancer
Oct 22, 2018: NCCN awarded $2 million in research funding from Taiho Oncology to study Trifluridine and Tipiracil in various cancers
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Rectal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Rectal Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Rectal Cancer - Pipeline by Advaxis Inc, 2022
Rectal Cancer - Pipeline by Alkermes Plc, 2022
Rectal Cancer - Pipeline by Amphivena Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Apexigen Inc, 2022
Rectal Cancer - Pipeline by AptaBio Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Arcus Biosciences Inc, 2022
Rectal Cancer - Pipeline by AstraZeneca Plc, 2022
Rectal Cancer - Pipeline by BeiGene Ltd, 2022
Rectal Cancer - Pipeline by Beijing Konruns Pharmaceutical Co Ltd, 2022
Rectal Cancer - Pipeline by BioAtla Inc, 2022
Rectal Cancer - Pipeline by Biomimetix JV LLC, 2022
Rectal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022
Rectal Cancer - Pipeline by CytomX Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Diverse Biotech Inc, 2022
Rectal Cancer - Pipeline by Eisai Co Ltd, 2022
Rectal Cancer - Pipeline by Eli Lilly and Co, 2022
Rectal Cancer - Pipeline by Ellipses Pharma Ltd, 2022
Rectal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022
Rectal Cancer - Pipeline by Genentech USA Inc, 2022
Rectal Cancer - Pipeline by Genexine Inc, 2022
Rectal Cancer - Pipeline by Genome & Co, 2022
Rectal Cancer - Pipeline by GlaxoSmithKline Plc, 2022
Rectal Cancer - Pipeline by Harbin Gloria Pharmaceuticals Co Ltd, 2022
Rectal Cancer - Pipeline by Hutchison MediPharma Ltd, 2022
Rectal Cancer - Pipeline by Incyte Corp, 2022
Rectal Cancer - Pipeline by Innovent Biologics Inc, 2022
Rectal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Rectal Cancer - Pipeline by LipoMedix Pharmaceutical Inc, 2022
Rectal Cancer - Pipeline by Merck & Co Inc, 2022
Rectal Cancer - Pipeline by Merck KGaA, 2022
Rectal Cancer - Pipeline by Millennium Pharmaceuticals Inc, 2022
Rectal Cancer - Pipeline by Novartis AG, 2022
Rectal Cancer - Pipeline by Oncolys BioPharma Inc, 2022
Rectal Cancer - Pipeline by OncXerna Therapeutics Inc, 2022
Rectal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022
Rectal Cancer - Pipeline by Pieris Pharmaceuticals Inc, 2022
Rectal Cancer - Pipeline by Precigen Inc, 2022
Rectal Cancer - Pipeline by Privo Technologies Inc, 2022
Rectal Cancer - Pipeline by Sanofi, 2022
Rectal Cancer - Pipeline by Shanghai Haihe Biopharma Co Ltd, 2022
Rectal Cancer - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Rectal Cancer - Pipeline by SQZ Biotechnologies Co, 2022
Rectal Cancer - Pipeline by Taiho Oncology Inc, 2022
Rectal Cancer - Pipeline by Teon Therapeutics Inc, 2022
Rectal Cancer - Dormant Projects, 2022
Rectal Cancer - Discontinued Products, 2022